Schematic overview over beamline P09 and the optical components in the beam path.
P09 is open to applications for beam time
The XMCD program at P09 has come to a full stop in July of 2022 following a strategic decision of the DESY directors in December of 2021 to build a macromolecular crystallography set up dedicated to high-throughput pharmaceutical X-ray screening in the 3rd experimental hutch of P09 and allocate to it 30% of the total beamtime available at P09. This setting is anticipated to be continued until the end of the year 2026.
Users can apply for the following stations:
-> P09 Resonant Scattering and Diffraction stations, dedicated to resonant and magnetic X-ray diffraction experiments on single crystals and thin films in the tender and hard X-ray range and operated by the DESY FS-P09 team.
-> P09 HiPhax enstation, dedicated to high-throughput pharmaceutical X-ray screening and operated by the DESY FS-BMX group.
